Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11148-E11157. doi: 10.1073/pnas.1805436115. Epub 2018 Nov 5.

Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model.

Author information

1
Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136.
2
Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL 33136.
3
Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136; CVolmar@med.miami.edu cwahlestedt@med.miami.edu.
4
Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL 33136.

Abstract

Alzheimer's disease (AD) is the leading cause of age-related dementia. Neuropathological hallmarks of AD include brain deposition of β-amyloid (Aβ) plaques and accumulation of both hyperphosphorylated and acetylated tau. RGFP-966, a brain-penetrant and selective HDAC3 inhibitor, or HDAC3 silencing, increases BDNF expression, increases histone H3 and H4 acetylation, decreases tau phosphorylation and tau acetylation at disease-associated sites, reduces β-secretase cleavage of the amyloid precursor protein (APP), and decreases Aβ1-42 accumulation in HEK-293 cells overexpressing APP with the double Swedish mutation (HEK/APPsw). In the triple transgenic AD mouse model (3xTg-AD), repeated administration of 3 and 10 mg/kg of RGFP-966 reverses pathological tau phosphorylation at Thr181, Ser202, and Ser396, increases levels of the Aβ degrading enzyme Neprilysin in plasma, decreases Aβ1-42 protein levels in the brain and periphery, and improves spatial learning and memory. Finally, we show that RGFP-966 decreases Aβ1-42 accumulation and both tau acetylation and phosphorylation at disease residues in neurons derived from induced pluripotent stem cells obtained from APOEε4-carrying AD patients. These data indicate that HDAC3 plays an important regulatory role in the expression and regulation of proteins associated with AD pathophysiology, supporting the notion that HDAC3 may be a disease-modifying therapeutic target.

KEYWORDS:

Alzheimer’s disease; HDACs; epigenetics; histone deacetylase 3 inhibitor; tau posttranslational modifications

PMID:
30397132
PMCID:
PMC6255210
DOI:
10.1073/pnas.1805436115
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center